LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 117 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2021. The put-call ratio across all filers is 0.40 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $47,730 | -16.3% | 40,449 | 0.0% | 0.00% | – |
| Q2 2023 | $57,033 | -6.0% | 40,449 | 0.0% | 0.00% | – |
| Q1 2023 | $60,674 | +108246.4% | 40,449 | -16.5% | 0.00% | – |
| Q4 2022 | $56 | -99.9% | 48,464 | 0.0% | 0.00% | – |
| Q3 2022 | $55,000 | -46.6% | 48,464 | -25.6% | 0.00% | – |
| Q2 2022 | $103,000 | -48.0% | 65,155 | -49.4% | 0.00% | – |
| Q1 2022 | $198,000 | -37.1% | 128,683 | 0.0% | 0.00% | – |
| Q4 2021 | $315,000 | -2.8% | 128,683 | 0.0% | 0.00% | – |
| Q3 2021 | $324,000 | -11.7% | 128,683 | 0.0% | 0.00% | – |
| Q2 2021 | $367,000 | +21.5% | 128,683 | 0.0% | 0.00% | – |
| Q1 2021 | $302,000 | +37.9% | 128,683 | +3.5% | 0.00% | – |
| Q4 2020 | $219,000 | +88.8% | 124,360 | 0.0% | 0.00% | – |
| Q3 2020 | $116,000 | -8.7% | 124,360 | -14.9% | 0.00% | – |
| Q2 2020 | $127,000 | +1.6% | 146,088 | -3.6% | 0.00% | – |
| Q1 2020 | $125,000 | -7.4% | 151,487 | 0.0% | 0.00% | – |
| Q4 2019 | $135,000 | -11.2% | 151,487 | -2.2% | 0.00% | – |
| Q3 2019 | $152,000 | – | 154,850 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,935,485 | $41,223,872 | 3.66% |
| Raffles Associates | 1,587,739 | $1,873,532 | 2.48% |
| Defender Capital, LLC. | 5,184,510 | $6,117,722 | 2.22% |
| Prescott General Partners LLC | 1,851,851 | $2,185,184 | 0.14% |
| DCF Advisers, LLC | 82,751 | $97,646 | 0.05% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $63,450 | 0.05% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 781,766 | $922,484 | 0.02% |
| Fort Sheridan Advisors LLC | 83,931 | $99,039 | 0.02% |
| MAI Capital Management | 954,688 | $1,126,532 | 0.02% |
| Piscataqua Savings Bank | 12,499 | $14,623 | 0.01% |